...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMJ: British medical journal >SHORT CUTS
【24h】

SHORT CUTS

机译：捷径

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Tanezumab is a monoclonal antibody directed against nerve growth factor, one of the mediators of pain in damaged or inflamed tissue. This new agent has analgesic potential, and an early trial reports good results for people with severe osteoarthritis of the knee. Two infusions of tanezumab at a variety of doses significantly improved objective measures of pain over 16 weeks, relative to a placebo control (improvement of 45-62% v 22% for controls; P< 0.001). So it is effective, but is it safe? The US Food and Drug Administration (FDA) is already worried about this new biological analgesic and has suspended three further trials while researchers investigate the role of tanezumab in 16 cases of joint failure that emerged earlier this year.
机译：Tanezumab单克隆抗体导向对神经生长因子、介质之一受损或发炎疼痛的组织。代理有镇痛潜力,和早期的试验报告患有严重的好结果骨关节炎的膝盖。tanezumab多种显著的剂量改进的目标措施的痛苦超过16周,相对于安慰剂控制的改进45 - 62% v控制为22%;有效,但它是安全的呢?管理局(FDA)已经担心这种新生物镇痛和已暂停三个进一步的试验研究调查tanezumab的16例的作用今年早些时候联合故障出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号